ClinicalTrials.gg

Lung Neoplasms clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 5,427 studies for Lung Neoplasms across more than 10 countries. 1,345 are recruiting or about to start. 2,752 of them are mainly about Lung Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 8 narrower conditions too, such as Carcinoma, Non-Small-Cell Lung: 12,592 studies, 3,219 open.

ClinicalTrials.gov finds 14,722 studies for Lung Neoplasms. How that becomes 5,423 here

This page counts the studies the registry files under Lung Neoplasms, and those it files under no condition that list Lung Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 14,722Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −7,142Filed under a narrower condition, counted on its own pageCarcinoma, Non-Small-Cell Lung 5,320 · Small Cell Lung Carcinoma 731 · Mesothelioma, Malignant 254 · Adenocarcinoma of Lung 132 · Multiple Pulmonary Nodules 57 · Carcinoma, Bronchogenic 17 · 2 more
  3. −174List Lung Neoplasms as a condition, but the registry did not file them under itMost often written as “Lung Cancer Screening” (11), “Squamous Cell Lung Cancer” (9), and “Non-small Cell Lung Cancer Metastatic” (7). The registry filed them under other conditions only, most often Neoplasms (22) and Neoplasm Metastasis (21).
  4. −1,983Match it another way663 name it in the title, 34 in a keyword, and 1,286 by a synonym or other text the search reads.
  5. 5,423The count on this page147 of them list Lung Neoplasms in their own words; the registry filed them under no condition.

Status

Completed
2,377
Recruiting
995
Status unknown
627
Terminated
509
Active, not recruiting
357
Not yet recruiting
312

Phase

Phase 2
1,458
Phase 1
895
Phase 3
366
Phase 4
73
Early Phase 1
65

Where

United States
2,460
China
845
France
399
Canada
382
Italy
299
United Kingdom
276

Who develops what

Add Lung Neoplasms to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 92 programs from 59 companies, 38 with this as their studies’ main aim; 18 with a live phase 3 study; 19 primary completions in the next 12 months. Compare Merck, Pfizer and Jiangsu HengRui Medicine here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
CarboplatinRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07777822 · Revolution Medicines, Inc. · Phase 3 · live · background · “pemetrexed + cisplatin /carboplatin” · registered Aug 2026
  • NCT07625644 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin” · registered May 2026
  • NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Carboplatin” · registered Mar 2026
  • NCT07486817 · Boehringer Ingelheim · Phase 2 · live · background · “Carboplatin” · registered Mar 2026
  • NCT07229599 · Minghui Pharmaceutical · Phase 2 · live · background · “Carboplatin” · registered Nov 2025
Eli Lilly and Company16% of its industry studies1524 studies
pembrolizumabRecent, repeated
Evidence
  • NCT07777822 · Revolution Medicines, Inc. · Phase 3 · live · background · “pembrolizumab” · registered Aug 2026
  • NCT07223047 · Bristol-Myers Squibb · Phase 2 · live · background · “Pembrolizumab” · registered Oct 2025
  • NCT07222566 · Pfizer · Phase 3 · live · comparator · “Pembrolizumab” · registered Oct 2025
  • NCT07162883 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Keytruda®” · registered Aug 2025
  • NCT07063745 · Bristol-Myers Squibb · Phase 3 · live · background · “Pembrolizumab” · registered Jul 2025
Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015)1419 studies
PemetrexedRecent, repeated
Evidence
  • NCT07777822 · Revolution Medicines, Inc. · Phase 3 · live · background · “pemetrexed + cisplatin /carboplatin” · registered Aug 2026
  • NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Pemetrexed” · registered Mar 2026
  • NCT07486817 · Boehringer Ingelheim · Phase 2 · live · background · “Pemetrexed” · registered Mar 2026
  • NCT07154368 · Guangzhou JOYO Pharma Co., Ltd · Phase 3 · live · background · “Pemetrexed injection” · registered Aug 2025
  • NCT07100080 · Bristol-Myers Squibb · Phase 3 · live · comparator · “Pemetrexed” · registered Jul 2025
Eli Lilly and Company67% of its industry studiesUS: off-patent, 4 generics marketedEU: off-patent, 3 generics authorized1018 studies
DocetaxelRecent, repeated
Evidence
  • NCT06881784 · Revolution Medicines, Inc. · Phase 3 · live · comparator · “docetaxel” · registered Mar 2025
  • NCT06780098 · Merck & Co., Inc · Phase 2 · live · comparator · “Docetaxel” · registered Jan 2025
  • NCT06635824 · Genmab · Phase 3 · live · comparator · “Docetaxel” · registered Oct 2024
  • NCT06228326 · Krystal Biotech, Inc. · Phase 2 · live · background · “Docetaxel” · registered Jan 2024
  • NCT06012435 · Pfizer · Phase 3 · live · comparator · “docetaxel” · registered Aug 2023
Sanofi27% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized88 studies
CisplatinRecent, repeated
Evidence
  • NCT07777822 · Revolution Medicines, Inc. · Phase 3 · live · background · “pemetrexed + cisplatin /carboplatin” · registered Aug 2026
  • NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Cisplatin” · registered Mar 2026
  • NCT07486817 · Boehringer Ingelheim · Phase 2 · live · background · “Cisplatin” · registered Mar 2026
  • NCT07100080 · Bristol-Myers Squibb · Phase 3 · live · comparator · “Cisplatin” · registered Jul 2025
  • NCT07063745 · Bristol-Myers Squibb · Phase 3 · live · background · “Cisplatin” · registered Jul 2025
Eli Lilly and Company28% of its industry studiesUS: off-patent, 6 generics marketed714 studies
PaclitaxelRecent, repeated
Evidence
  • NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Paclitaxel” · registered Mar 2026
  • NCT07063745 · Bristol-Myers Squibb · Phase 3 · live · background · “Paclitaxel” · registered Jul 2025
  • NCT06788912 · Merck & Co., Inc · Phase 2 · live · comparator · “Paclitaxel” · registered Jan 2025
  • NCT06731907 · Merck & Co., Inc · Phase 2 · live · comparator · “Paclitaxel” · registered Dec 2024
  • NCT06712316 · BioNTech SE · Phase 3 · live · background · “Paclitaxel” · registered Nov 2024
Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed48 studies
osimertinibRecent, repeated
Evidence
  • NCT07285148 · Beijing Pearl Biotechnology Limited Liability Company · Phase 2 · live · comparator · “ANS014004 + Osimertinib” · registered Nov 2025
  • NCT06618287 · Bristol-Myers Squibb · Phase 2 · live · background · “Osimertinib” · registered Sep 2024
  • NCT06574347 · Avistone Biotechnology Co., Ltd. · Phase 2 · live · comparator · “Osimertinib” · registered Aug 2024
  • NCT05498389 · Shanghai EpimAb Biotherapeutics Co., Ltd. · Phase 2 · live · background · “Osimertinib” · registered Jun 2022
  • NCT03989115 · Revolution Medicines, Inc. · Phase 2 · background · “Drug: Osimertinib” · registered Jun 2019
AstraZeneca93% of its industry studiesUS: AstraZeneca (FDA 2015)EU: AstraZeneca (EMA 2016)44 studies
GemcitabineRecent, repeated
Evidence
  • NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Gemcitabine” · registered Mar 2026
  • NCT07223047 · Bristol-Myers Squibb · Phase 2 · live · background · “Gemcitabine” · registered Oct 2025
  • NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Gemcitabine + Nab-paclitaxel” · registered May 2025
  • NCT06788912 · Merck & Co., Inc · Phase 2 · live · comparator · “Gemcitabine” · registered Jan 2025
  • NCT06312137 · Merck & Co., Inc · Phase 3 · live · background · “Gemcitabine” · registered Mar 2024
Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed35 studies
Albumin-Bound PaclitaxelRecent, repeated
Evidence
  • NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Gemcitabine + Nab-paclitaxel” · registered May 2025
  • NCT06731907 · Merck & Co., Inc · Phase 2 · live · comparator · “Nab-paclitaxel” · registered Dec 2024
  • NCT05633667 · Gilead Sciences · Phase 2 · live · comparator · “Nab-paclitaxel” · registered Nov 2022
  • NCT05014815 · BeOne Medicines · Phase 2 · background · “Nab paclitaxel” · registered Aug 2021
  • NCT04222972 · Hoffmann-La Roche · Phase 3 · comparator · “Nab-Paclitaxel” · registered Jan 2020
Bristol-Myers Squibb43% of its industry studiesEU: Bristol-Myers Squibb (EMA 2008)33 studies
EtoposideRecent, repeated
Evidence
  • NCT07625644 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin” · registered May 2026
  • NCT06712355 · BioNTech SE · Phase 3 · live · background · “Etoposide” · registered Nov 2024
  • NCT05652686 · Phanes Therapeutics · Phase 2 · live · background · “Carboplatin + Etoposide” · registered Dec 2022
  • NCT04380636 · Merck & Co., Inc · Phase 3 · live · background · “Etoposide” · registered May 2020
  • NCT03699956 · EpicentRx, Inc. · Phase 3 · background · “Cisplatin/carboplatin plus etoposide” · registered Oct 2018
Hoffmann-La Roche14% of its industry studiesUS: off-patent, 5 generics marketed33 studies
CetuximabRecent, repeated
Evidence
  • NCT07286149 · Merck & Co., Inc · Phase 2 · live · background · “Cetuximab” · registered Nov 2025
  • NCT07223047 · Bristol-Myers Squibb · Phase 2 · live · background · “Cetuximab” · registered Oct 2025
  • NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Cetuximab” · registered May 2025
Eli Lilly and Company33% of its industry studiesUS: Eli Lilly and Company (FDA 2004)EU: Merck KGaA, Darmstadt, Germany (EMA 2004)33 studies
Antineoplastic AgentsRecent, repeated
Evidence
  • NCT07476287 · Pfizer · Phase 2 · live · background · “Chemotherapy” · registered Mar 2026
  • NCT06228326 · Krystal Biotech, Inc. · Phase 2 · live · background · “Chemotherapy” · registered Jan 2024
  • NCT04495153 · Candel Therapeutics, Inc. · Phase 2 · live · background · “Chemotherapy” · registered Jul 2020
  • NCT02873416 · ningbo cancer hospital · Phase 2 · background · “Chemotherapy” · registered Aug 2016
  • NCT02862587 · Shanghai International Medical Center · Phase 2 · background · “Chemotherapy” · registered Aug 2016
—22 studies
IrinotecanRecent, repeated
Evidence
  • NCT05652686 · Phanes Therapeutics · Phase 2 · live · background · “Irinotecan (drug)” · registered Dec 2022
  • NCT05592626 · Marengo Therapeutics, Inc. · Phase 2 · live · background · “Irinotecan (Camptosar)” · registered Oct 2022
  • NCT03678883 · Actuate Therapeutics Inc. · Phase 2 · live · background · “Irinotecan” · registered Sep 2018
  • NCT02489903 · EpicentRx, Inc. · Phase 2 · comparator · “Irinotecan” · registered Jun 2015
Pfizer17% of its industry studiesUS: off-patent, 7 generics marketedEU: Les Laboratoires des Médicaments Stériles (EMA 2016)22 studies
atezolizumabRecent, repeated
Evidence
  • NCT07625644 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin” · registered May 2026
  • NCT06712355 · BioNTech SE · Phase 3 · live · comparator · “Atezolizumab” · registered Nov 2024
  • NCT04471727 · Merck & Co., Inc · Phase 2 · live · background · “Atezolizumab” · registered Jul 2020
Hoffmann-La Roche91% of its industry studiesUS: Hoffmann-La Roche (FDA 2016)EU: Hoffmann-La Roche (EMA 2017)22 studies
lurbinectedinRecent, repeated
Evidence
  • NCT07625644 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin” · registered May 2026
  • NCT05652686 · Phanes Therapeutics · Phase 2 · live · background · “Lurbinectedin” · registered Dec 2022
PharmaMar74% of its industry studiesUS: JAZZ (FDA 2020)EU: Pharma Mar S.A. (EMA 2026)22 studies

30 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
zongertinibApproved: US 2025☆ Track1 live phase-3 study: NCT06151574Boehringer Ingelheim
Fudotinib☆ Track1 live phase-3 study: NCT07154368Guangzhou JOYO Pharma Co., Ltd
risvutatug rezetecan☆ Track1 live phase-3 study: NCT07099898GlaxoSmithKline
izalontamab brengitecan☆ Track1 live phase-3 study: NCT07100080Bristol-Myers Squibb
zipalertinib☆ Track1 live phase-3 study: NCT07128199Otsuka Holdings Co., Ltd.

The 5 in phase 3 with the nearest primary completion, of 92 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (19)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.andamertinib · Avistone Biotechnology Co., Ltd. · Phase 2 named, not the main aimNCT07336732 Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations — primary endpoint: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]). · 40 enrolled
  • 10 Dec 2026 est.zongertinib · Boehringer Ingelheim · Phase 3 main aimvs Carboplatinvs pembrolizumabvs PemetrexedNCT06151574 Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment — primary endpoint: Progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 determined by blinded central independent review · 428 enrolled
  • 30 Dec 2026 est.Anti-Claudin 18.2 Antibody-drug Conjugate ASP546C · Astellas Pharma Inc · Phase 2 main aimNCT06792435 XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. — primary endpoint: Phase I (Dose Escalation):To determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of XNW27011 · 240 enrolled

16 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Lung Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 61 open · Tyrosine kinase inhibitors (TKIs) 52 open · Antibody-drug conjugates (ADCs) 12 open · Antimetabolites 11 open · Angiogenesis inhibitors 9 open

Coming up

536studies finish main data collection within a year18 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger. 45 (5%) take children under 18. 6 (1%) are for women only and 2 (<1%) for men only; 142 (14%) take healthy volunteers.

Recruiting studies that take each age, of 995
AgeWomenMen
1037 (4%)37 (4%)
18837 (84%)833 (84%)
30893 (90%)889 (89%)
40913 (92%)909 (91%)
50970 (97%)966 (97%)
65986 (99%)982 (99%)
75945 (95%)942 (95%)
85755 (76%)752 (76%)

Across all 5,424 studies, recruiting or not: 12% stop at 75 or younger and 2% at 65; 6% take children; 1% are for women only and <1% for men only; 10% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Lung Neoplasms studies take

Of 364 phase 2 interventional studies under Lung Neoplasms, half reached primary completion within 65 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 152 mo28–74 · 291 studies41 mo25–57 · 128 studies60 mo35–90 · 163 studies
Phase 1/254 mo40–93 · 157 studies48 mo37–82 · 79 studies60 mo44–159 · 78 studies
Phase 265 mo34–105 · 364 studies37 mo23–61 · 77 studies72 mo43–113 · 287 studies
Phase 344 mo30–80 · 128 studies36 mo23–44 · 62 studies66 mo42–99 · 66 studies
Phase 435 mo24–67 · 28 studies——
Interventional, no phase34 mo15–67 · 916 studies17 mo8–34 · 51 studies35 mo16–68 · 865 studies
Observational57 mo25–135 · 682 studies48 mo24–58 · 90 studies65 mo25–162 · 592 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Started recruiting17

Show 12 more

Newly registered29

Show 24 more

Studies

Recruiting first, then most recently updated. Showing 50 of 5,427. Browse all 5,427 → or search them.